Cargando…

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

Background. Parkinson's disease (PD) remains a clinical diagnosis and biomarkers are needed to detect the disease as early as possible. Genetically determined PD provides an opportunity for studying metabolic differences in connection with disease development. Objectives. To study the levels of...

Descripción completa

Detalles Bibliográficos
Autores principales: Aasly, Jan O., Sæther, Oddbjørn, Johansen, Krisztina K., Bathen, Tone F., Giskeødegård, Guro F., White, Linda R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556333/
https://www.ncbi.nlm.nih.gov/pubmed/26357583
http://dx.doi.org/10.1155/2015/264896
_version_ 1782388336820748288
author Aasly, Jan O.
Sæther, Oddbjørn
Johansen, Krisztina K.
Bathen, Tone F.
Giskeødegård, Guro F.
White, Linda R.
author_facet Aasly, Jan O.
Sæther, Oddbjørn
Johansen, Krisztina K.
Bathen, Tone F.
Giskeødegård, Guro F.
White, Linda R.
author_sort Aasly, Jan O.
collection PubMed
description Background. Parkinson's disease (PD) remains a clinical diagnosis and biomarkers are needed to detect the disease as early as possible. Genetically determined PD provides an opportunity for studying metabolic differences in connection with disease development. Objectives. To study the levels of intermediary metabolites in cerebrospinal fluid (CSF) from patients with PD, either of sporadic type or in carriers of the LRRK2 p.G2019S mutation. Methods. Results from patients with sporadic PD or LRRK2-PD were compared with asymptomatic LRRK2 mutation carriers and healthy control individuals. CSF was analysed by proton MR spectroscopy ((1)H-MRS) giving reliable results for 16 intermediary metabolites. Partial least squares discriminant analysis (PLS-DA) was applied to study group differences. Results. PLS-DA distinguished PD patients from healthy individuals based on the metabolites identified in CSF, with 2-hydroxybutyrate, glutamine, and dimethyl sulphone largely contributing to the separations. Conclusion. Speculatively, all three metabolites could alter concentration in response to metabolic changes connected with neurodegeneration; glutamine as a means of removing excess nitrogen from brain, dimethyl sulphone as an anti-inflammatory agent, and 2-hydroxybutyrate in connection with altered glutathione metabolism. Potentially, (1)H-MRS is a promising tool for identifying novel biomarkers for PD.
format Online
Article
Text
id pubmed-4556333
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45563332015-09-09 Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy Aasly, Jan O. Sæther, Oddbjørn Johansen, Krisztina K. Bathen, Tone F. Giskeødegård, Guro F. White, Linda R. Parkinsons Dis Research Article Background. Parkinson's disease (PD) remains a clinical diagnosis and biomarkers are needed to detect the disease as early as possible. Genetically determined PD provides an opportunity for studying metabolic differences in connection with disease development. Objectives. To study the levels of intermediary metabolites in cerebrospinal fluid (CSF) from patients with PD, either of sporadic type or in carriers of the LRRK2 p.G2019S mutation. Methods. Results from patients with sporadic PD or LRRK2-PD were compared with asymptomatic LRRK2 mutation carriers and healthy control individuals. CSF was analysed by proton MR spectroscopy ((1)H-MRS) giving reliable results for 16 intermediary metabolites. Partial least squares discriminant analysis (PLS-DA) was applied to study group differences. Results. PLS-DA distinguished PD patients from healthy individuals based on the metabolites identified in CSF, with 2-hydroxybutyrate, glutamine, and dimethyl sulphone largely contributing to the separations. Conclusion. Speculatively, all three metabolites could alter concentration in response to metabolic changes connected with neurodegeneration; glutamine as a means of removing excess nitrogen from brain, dimethyl sulphone as an anti-inflammatory agent, and 2-hydroxybutyrate in connection with altered glutathione metabolism. Potentially, (1)H-MRS is a promising tool for identifying novel biomarkers for PD. Hindawi Publishing Corporation 2015 2015-08-18 /pmc/articles/PMC4556333/ /pubmed/26357583 http://dx.doi.org/10.1155/2015/264896 Text en Copyright © 2015 Jan O. Aasly et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aasly, Jan O.
Sæther, Oddbjørn
Johansen, Krisztina K.
Bathen, Tone F.
Giskeødegård, Guro F.
White, Linda R.
Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title_full Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title_fullStr Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title_full_unstemmed Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title_short Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
title_sort changes to intermediary metabolites in sporadic and lrrk2 parkinson's disease demonstrated by proton magnetic resonance spectroscopy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556333/
https://www.ncbi.nlm.nih.gov/pubmed/26357583
http://dx.doi.org/10.1155/2015/264896
work_keys_str_mv AT aaslyjano changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy
AT sætheroddbjørn changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy
AT johansenkrisztinak changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy
AT bathentonef changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy
AT giskeødegardgurof changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy
AT whitelindar changestointermediarymetabolitesinsporadicandlrrk2parkinsonsdiseasedemonstratedbyprotonmagneticresonancespectroscopy